NEW ON THE POD: In this episode, I talk with two of the people most responsible for re-wiring the employer side of healthcare right now: Dan Mendelson @dnmendelson, CEO of @MorganHealth, JPMorgan Chase's $280M healthcare investment arm, and John Zutter, CEO of Lantern, a specialty care navigation platform now covering 12 million member lives. The conversation covers a lot of ground: how Lantern cracked the code on surgeons of excellence at a community level, why Dan thinks traditional payor networks are failing, the $10M cell & gene therapy math nobody at the employer level wants to run, and whether AI finally makes narrow networks work this time around. They get into the real cost drivers: specialty care, oncology, infusions, and specialty drugs represent about 60% of total employer healthcare spend — and they're all growing 1.5x to 3x faster than overall trend. John lays it out in numbers most CFOs don't see clearly enough. If you sell into employers, sit on a benefits committee, run a self-funded plan, or invest in this corner of the market, this is one I'd block off the time for. Drop me a note on what stuck. Apple: Spotify: TIMESTAMPS (00:00) From "fifth CEO in less than five years" to 12M lives: how Lantern actually turned around (and why "Centers of Excellence" had to die for "Surgeons of Excellence" to live) (11:39) Morgan Health rises from the ashes of Haven — Dan's favorite topic, allegedly (17:45) "Are you friend or foe?" — the call Dan got from a Big Five payer CEO right after Jamie went public (27:00) The 5% problem: John runs a clinic on where employer dollars actually go (mandatory listening — pull out a notepad) (40:00) $10M per dose, 12 months on payroll: the cell & gene therapy time-horizon problem nobody at the employer level wants to answer (50:30) HMO 2.0: why narrow networks plus AI might finally work, 30 years after the last attempt blew up